Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen to Develop Breast Cancer Diagnostics

NEW YORK, Dec. 9 (GenomeWeb News) - Ciphergen Biosystems said yesterday that it is developing breast cancer diagnostics based on a "series of discoveries" that have been made using the company's SELDI technology.

 

Ciphergen cited a study by researchers at the Johns Hopkins School of Medicine, published in Clinical Chemistry in 2002, that detailed the discovery of three serum biomarkers that can improve the detection of breast cancer.

 

"Two out of the three markers have since been identified and validated in further studies that were published this month," the company said in a statement. The markers are named C3a and BC1.

 

Ciphergen said it plans to expand upon these studies in a collaboration with the University of College London and UCL BioMedica that will analyze samples collected from 200,000 women with breast and ovarian cancer.

 

Ciphergen did not provide a timeline for the development program.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.